Avidity Biosciences LLC

BridgeBio Pharma, Inc.BBIO · BiopharmaceuticalsPalo Alto, United States

66% matchPublicAI 34/100Green 2/100

BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.

Ambrx Biopharma was a clinical-stage biopharmaceutical company that developed antibody-drug conjugates and other targeted therapeutics using its proprietary expanded genetic code technology for site-specific protein modification. Its programs were aimed at treating cancers and served patients through partnerships and clinical development; Johnson & Johnson acquired Ambrx in 2024.

Alnylam Pharmaceuticals0HD2 · BiopharmaceuticalsCambridge, United States

66% matchPublic

Alnylam Pharmaceuticals is a leading RNAi therapeutics company founded in 2002 and headquartered in Cambridge, Massachusetts. The company focuses on the discovery, development, and commercialization of novel RNA interference therapeutics to address genetic and other human diseases, and operates manufacturing facilities such as its Norton site.

Endocyte was a biopharmaceutical company that developed targeted small-molecule drug conjugates and radioligand therapies for cancer. Its lead program, PSMA-targeted lutetium-177 PSMA-617, was acquired by Novartis in 2018 and later became the basis for Pluvicto, serving patients with prostate cancer.

Orbital Therapeutics is a biotechnology company developing RNA medicines, with a focus on engineered circular RNA and delivery technologies. Its programs are intended to address diseases that may benefit from durable, programmable protein expression, serving patients and healthcare providers through potential therapeutic products.

Aviceda Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on glyco-immune checkpoint therapeutics. The company develops novel, immune-mediated therapies designed to treat inflammatory and blinding diseases. Their proprietary technology platform leverages glycobiology to modulate the immune system for patient benefit.